Orion Pharma Limited announcements
187 Dhaka Stock Exchange announcements for Orion Pharma Limited (ORIONPHARM) since 2013: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2026 (6).
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 09, 2026 at 4:00 PM to consider, among others, annual audited financial statements of the Company for the year ended June 30, 2026.
- Q3 Financials
(Q3 Un-audited): Consolidated EPS was BDT (0.65) for January-March 2026 as against BDT 0.02 for January-March 2025; Consolidated EPS was BDT (0.95) for July 2025-March 2026 as against BDT (0.18) for July 2024-March 2025. Consolidated NOCFPS was BDT 4.06 for July 2025-March 2026 as against BDT 5.27 for July 2024-March 2025. (cont.) (cont. news of ORIONPHARM): Consolidated NAV per share (including revaluation surplus) was BDT 85.46 as on March 31, 2026, and BDT 86.09 as on June 30, 2025; consolidated NAV per share (excluding revaluation surplus) was BDT 77.72 as on March 31, 2026, and BDT 78.34 as on June 30, 2025. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2026 at 4:00 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.
- Q2 Financials
(Q2 Un-audited): Consolidated EPS was Tk. (0.56) for October-December 2025 as against Tk. (0.44) for October-December 2024; Consolidated EPS was Tk. (0.86) for July-December 2025 as against Tk. (0.20) for July-December 2024. Consolidated NOCFPS was Tk. 2.61 for July-December 2025 as against Tk. 4.26 for July-December 2024. Consolidated NAV per share with revaluation surplus was Tk. 85.74 as on December 31, 2025 and Tk. 86.09 as on June 30, 2025. (cont.) (Cont. News of ORIONPHARM): Consolidated NAV per share without revaluation surplus was Tk. 78.00 as on December 31, 2025 and Tk. 78.34 as on June 30, 2025. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2026 at 4:00 PM to consider, among others, Un-Audited Financial Statements for the Second Quarter (Q2) period ended December 31, 2025.
- Credit Rating Result
Credit Rating Agency of Bangladesh Limited (CRAB) has announced the surveillance entity rating of the Company as "A1" in the long term and "ST-4" in the short term along with Stable outlook based on audited financial statements (FYE 30/06/2025, 30/06/2024, 30/06/2023), bank liability as on 08/12/2025 and other information up to the date of rating declaration.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.